Esperion Therapeutics Inc (ESPR) FinancialsESPRFinancialEsperion Therapeutics Inc

Evaluating the bottom line, Esperion Therapeutics Inc maintains a gross margin of 56.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8.22%, while the net margin is -31.45%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ESPR converts its operational activities into shareholder value.

In the context of the broader market, ESPR competes directly with industry leaders such as GYRE and ZVRA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ESPR's gross margin of 56.84% stands against GYRE's 92.41% and ZVRA's 95.36%. Such benchmarking helps identify whether Esperion Therapeutics Inc is trading at a premium or discount relative to its financial performance.

No usable latest-quarter financial snapshot was provided due to an error, so there is no reliable quarter-by-quarter growth assessment available here. Based on the available data, the investment case is being driven by the acquisition terms rather than recent operating performance.